Tandem Diabetes Care Inc
NASDAQ:TNDM

Watchlist Manager
Tandem Diabetes Care Inc Logo
Tandem Diabetes Care Inc
NASDAQ:TNDM
Watchlist
Price: 18.89 USD 0.85% Market Closed
Market Cap: 1.3B USD

During the last 3 months Tandem Diabetes Care Inc insiders bought 191k USD , and have not sold any shares. The stock price has dropped by 49% over this period (open performance analysis).

The last transaction was made on Mar 7, 2025 by Kyrillos Jean-Claude (Executive Vice President & Chief Commercial Officer) , who bought 191k USD worth of TNDM shares.

Last Transactions:
Kyrillos Jean-Claude
Executive Vice President & Chief Commercial Officer
$+191k
Blickenstaff Kim D
Director
$-941.4k
Allen Dick
Executive Vice President and Chief Commercial Officer
$-258.4k
Allen Dick
Executive Vice President and Chief Commercial Officer
$+94.8k
Vosseller Leigh
Senior Vice President and General Counsel
$+95.4k
Hansen Shannon Marie
Executive Vice President, Chief Financial Officer, Principal Accounting Officer and Treasurer
$+29.9k
Mcgroddy-Goetz Kathleen
EVP, R&D, and Chief Technology Officer
$+21.5k
Allen Dick
Executive Vice President and Chief Commercial Officer
$+294.7k
Howell Peyton R
$+90.5k
Vosseller Leigh
Senior Vice President and General Counsel
$+98.8k
Berger David B
Chief Officer
$-411.9k
Berger David B
Chief Officer
$-604.8k
Berger David B
Chief Officer
$-455.2k
Blickenstaff Kim D
Director
$-999.9k
Sheridan John F
Member of the Board of Directors
$+174.8k
Vosseller Leigh
Senior Vice President and General Counsel
$+76.6k
Howell Peyton R
Chief Commercial Officer
$+7.5k
Twomey Christopher J
Executive Vice President, Chief Operating Officer
$-17.7k
Robertson Rebecca B
Independent Director
$-51.2k
Robertson Rebecca B
Independent Director
$-51.2k
Berger David B
Chief Officer
$-117.9k
Berger David B
Chief Officer
$-541.8k
Mcgroddy-Goetz Kathleen
EVP, R&D, and Chief Technology Officer
$-42.9k
Berger David B
Chief Officer
$-112.7k
Robertson Rebecca B
Independent Director
$-35k
Berger David B
Chief Officer
$-28.2k
Berger David B
Chief Officer
$-123.6k
Gasser Elizabeth Anne
Executive Vice President, Strategy & Corporate Development
$-55.8k
Leal James
Chief Operating Officer
$-81.5k
Berger David B
Chief Officer
$-1.7m
Gasser Elizabeth Anne
Executive Vice President, Strategy & Corporate Development
$-151.6k
Berger David B
Chief Officer
$-115.5k
View All Transactions

During the last 3 months Tandem Diabetes Care Inc insiders bought 191k USD , and have not sold any shares. The stock price has dropped by 49% over this period (open performance analysis).

The last transaction was made on Mar 7, 2025 by Kyrillos Jean-Claude (Executive Vice President & Chief Commercial Officer) , who bought 191k USD worth of TNDM shares.

Sold
0-3
months
0 USD
0
3-6
months
941.4k USD
1
6-9
months
0 USD
0
9-12
months
258.4k USD
1
Bought
0-3
months
1
191k USD
3-6
months
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
0
0 USD

Tandem Diabetes Care Inc
Insider Trading Chart

Tandem Diabetes Care Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Tandem Diabetes Care Inc
Last Insider Transactions

Global
Insiders Monitor

Tandem Diabetes Care Inc
Glance View

Market Cap
1.3B USD
Industry
Health Care

Tandem Diabetes Care Inc., a prominent figure in the healthcare sector, has carved out a notable niche with its innovative diabetes management solutions. Founded in 2006 and headquartered in San Diego, California, the company has become a leader in providing advanced insulin pump technologies. Central to Tandem’s business model is their flagship product, the t:slim X2 Insulin Pump, a sleek and user-friendly device praised for its ease of use and functionality. Through meticulous engineering and design, Tandem has positioned itself at the forefront of modern diabetes management by enhancing user experience and integrating advanced technologies such as continuous glucose monitoring (CGM) compatibility, making diabetes care more dynamic and responsive. Revenue for Tandem Diabetes Care primarily flows from the sale of these insulin pumps, along with associated supplies and accessories, which are crucial for ongoing diabetes management. The company also generates income through software and technology upgrades. By offering a subscription-based model, Tandem ensures steady revenue from the continual acquisition of consumables and technology updates, fostering customer loyalty and long-term engagement. Their commitment to innovation and patient-centric solutions has not only allowed them to tap into a growing market of diabetes patients seeking improved quality of life but has also strengthened their competitive edge in a rapidly evolving healthcare landscape.

TNDM Intrinsic Value
24.01 USD
Undervaluation 21%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top